Guangdong, China

Yuanye Su

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Shenzhen Yandai Investment Co., Ltd. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Yuanye Su in Cancer Treatment

Introduction

Yuanye Su is an innovative inventor based in Guangdong, China. He has made significant contributions to the field of plant extraction and separation technology. His work focuses on developing solutions that can improve the quality of life for advanced cancer patients.

Latest Patents

Yuanye Su holds a patent for a polysaccharide compound with a defined molecular structure that can eliminate the toxic side effects of chemotherapy drugs. This invention is particularly relevant for patients who are no longer candidates for surgery and have a limited life expectancy. The molecular formula of the compound is (CHO). The active ingredient is obtained through the extraction of effective components under high temperature and high pressure. This polysaccharide is characterized by its water solubility, allowing for easy absorption by the human body. It offers antitumor effects and has proven efficacy in preventing tumor development in humans.

Career Highlights

Yuanye Su is associated with Shenzhen Yandai Investment Co., Ltd., where he continues to work on innovative solutions for cancer treatment. His dedication to research and development has positioned him as a key figure in the field.

Collaborations

Yuanye Su collaborates with notable colleagues, including Xuemin Chen and Chunming He, to further advance their research and innovations in cancer treatment.

Conclusion

Yuanye Su's contributions to the field of cancer treatment through his innovative polysaccharide compound highlight the potential for advancements in medical technology. His work aims to provide hope and improved outcomes for patients facing advanced cancer.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…